Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas.
作者信息
Ellin Fredrik, Maurer Matthew J, Srour Line, Farooq Umar, Jerkeman Mats, Connors Joseph M, Smedby Karin E, Bennani N Nora, Ansell Stephen M, Slack Graham W, Cerhan James R, Relander Thomas, Feldman Andrew L, Savage Kerry J
机构信息
Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
出版信息
Br J Haematol. 2019 Aug;186(3):e24-e27. doi: 10.1111/bjh.15859. Epub 2019 Mar 11.
Abstract
摘要
相似文献
1
Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas.NCCN-IPI、IPI和PIT评分作为外周T细胞淋巴瘤预后评估工具的比较。
Br J Haematol. 2019 Aug;186(3):e24-e27. doi: 10.1111/bjh.15859. Epub 2019 Mar 11.
2
Ukraine Data on Prognostic Factors and Treatment Outcomes in Patients with Peripheral T-Cell Lymphomas.乌克兰外周T细胞淋巴瘤患者预后因素及治疗结果的数据。
Klin Onkol. 2019 Fall;32(6):436-444. doi: 10.14735/amko2019436.
3
The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified.中性粒细胞与淋巴细胞比值是未特定的外周T细胞淋巴瘤患者的独立预后因素。
Leuk Lymphoma. 2016;57(1):58-62. doi: 10.3109/10428194.2015.1045897. Epub 2015 Jun 19.
4
[Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].[基于CHOP化疗方案治疗的外周T细胞淋巴瘤患者的NCCN国际预后指数（NCCN-IPI）的预后意义]
Zhonghua Xue Ye Xue Za Zhi. 2017 Sep 14;38(9):772-777. doi: 10.3760/cma.j.issn.0253-2727.2017.09.008.
5
Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry.丹麦淋巴瘤登记处基于人群的系统性外周T细胞淋巴瘤队列中临床试验资格和预后指标的评估。
Hematol Oncol. 2015 Dec;33(4):120-8. doi: 10.1002/hon.2153. Epub 2014 Jul 23.
6
Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.侵袭性非霍奇金淋巴瘤中免疫表型与国际预后指数的预后意义比较
Clin Lymphoma. 2003 Jun;4(1):52-5. doi: 10.3816/clm.2003.n.014.
7
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.比较真实世界中大型老年人群外周 T 细胞淋巴瘤中 IPI 和 PIT 的预后影响。
Sci Rep. 2023 Nov 4;13(1):19060. doi: 10.1038/s41598-023-46501-5.
8
A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score.基于 NCCN-IPI 和治疗后 Deauville 评分的结外外周 T 细胞淋巴瘤风险分层模型。
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2274-2284. doi: 10.1007/s00259-018-4093-1. Epub 2018 Jul 28.
9
Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas.侵袭性原发性肠道 B 细胞和 T/NK 细胞淋巴瘤的临床病理特征和治疗结局比较。
J Formos Med Assoc. 2021 Jan;120(1 Pt 2):293-302. doi: 10.1016/j.jfma.2020.10.001. Epub 2020 Oct 21.
10
Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification.外周T细胞淋巴瘤：根据欧美淋巴瘤修订分类定义的92例临床特征及预后因素
Leuk Lymphoma. 2003 Feb;44(2):241-9. doi: 10.1080/1042819021000030054.
引用本文的文献
1
Clinical scoring systems, molecular subtypes and baseline [F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma.用于弥漫性大B细胞淋巴瘤预后评估的临床评分系统、分子亚型及基线[F]FDG PET/CT图像分析
Cancer Imaging. 2024 Dec 18;24(1):168. doi: 10.1186/s40644-024-00810-8.
2
Hematopoietic stem cell transplantation to improve prognosis in aggressive monomorphic epitheliotropic intestinal T-cell lymphoma.造血干细胞移植改善侵袭性单形上皮趋化性肠道T细胞淋巴瘤的预后。
Front Oncol. 2024 Nov 21;14:1388623. doi: 10.3389/fonc.2024.1388623. eCollection 2024.
3
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.比较真实世界中大型老年人群外周 T 细胞淋巴瘤中 IPI 和 PIT 的预后影响。
Sci Rep. 2023 Nov 4;13(1):19060. doi: 10.1038/s41598-023-46501-5.
4
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.国际 T 细胞项目网络的局限性外周 T 细胞淋巴瘤 SALENTO 预后模型。
Blood Adv. 2023 Sep 12;7(17):5047-5054. doi: 10.1182/bloodadvances.2023010037.
5
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.TP53 突变可识别接受 CHOP 为基础的化疗的外周 T 细胞淋巴瘤的高危事件。
Blood Adv. 2023 Sep 12;7(17):5172-5186. doi: 10.1182/bloodadvances.2023009953.
6
Low Expression of CD5 and CD6 Is Associated with Poor Overall Survival for Patients with T-Cell Malignancies.CD5和CD6低表达与T细胞恶性肿瘤患者的总生存期较差相关。
J Oncol. 2022 Aug 9;2022:2787426. doi: 10.1155/2022/2787426. eCollection 2022.
7
Association of ST-T changes with all-cause mortality among patients with peripheral T-cell lymphomas.外周T细胞淋巴瘤患者中ST-T改变与全因死亡率的关联。
Open Med (Wars). 2022 Jul 12;17(1):1252-1258. doi: 10.1515/med-2022-0517. eCollection 2022.
8
High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma.跨膜蛋白244（TMEM244）的高表达与T细胞淋巴瘤患者的总生存期较差相关。
Biomark Res. 2022 Jul 12;10(1):46. doi: 10.1186/s40364-022-00395-z.
9
Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients.老年外周 T 细胞淋巴瘤患者合并症的影响：891 例国际回顾性分析。
Blood Adv. 2022 Apr 12;6(7):2120-2128. doi: 10.1182/bloodadvances.2021004269.
10
TNFAIP3 mutation may be associated with favorable overall survival for patients with T-cell lymphoma.TNFAIP3突变可能与T细胞淋巴瘤患者较好的总生存率相关。
Cancer Cell Int. 2021 Sep 15;21(1):490. doi: 10.1186/s12935-021-02191-5.
本文引用的文献
1
Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.真实世界外周 T 细胞淋巴瘤的预后因素和治疗数据：来自瑞典淋巴瘤登记处的一项研究。
Blood. 2014 Sep 4;124(10):1570-7. doi: 10.1182/blood-2014-04-573089. Epub 2014 Jul 8.
2
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.在利妥昔单抗时代治疗弥漫性大 B 细胞淋巴瘤患者的改良国际预后指数（NCCN-IPI）。
Blood. 2014 Feb 6;123(6):837-42. doi: 10.1182/blood-2013-09-524108. Epub 2013 Nov 21.
3
Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project.血管免疫母细胞性 T 细胞淋巴瘤的临床病理特征：国际外周 T 细胞淋巴瘤项目分析。
J Clin Oncol. 2013 Jan 10;31(2):240-6. doi: 10.1200/JCO.2011.37.3647. Epub 2012 Aug 6.
4
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.外周 T 细胞淋巴瘤，非特指型：国际外周 T 细胞淋巴瘤项目的 340 例报告。
Blood. 2011 Mar 24;117(12):3402-8. doi: 10.1182/blood-2010-09-310342. Epub 2011 Jan 26.
5
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.国际外周T细胞和自然杀伤/T细胞淋巴瘤研究：病理结果与临床结局
J Clin Oncol. 2008 Sep 1;26(25):4124-30. doi: 10.1200/JCO.2008.16.4558. Epub 2008 Jul 14.
6
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.在成人淋巴瘤研究组（GELA）试验中接受治疗的157例血管免疫母细胞性T细胞淋巴瘤患者的临床、生物学和病理特征。
Blood. 2008 May 1;111(9):4463-70. doi: 10.1182/blood-2007-08-105759. Epub 2008 Feb 21.
7
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.外周T细胞淋巴瘤，非特指型（PTCL-U）：一项回顾性多中心临床研究的新预后模型
Blood. 2004 Apr 1;103(7):2474-9. doi: 10.1182/blood-2003-09-3080. Epub 2003 Nov 26.
8
Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.国际预后因素指数对周围T细胞淋巴瘤患者的预测能力。
J Clin Oncol. 1997 Jun;15(6):2296-301. doi: 10.1200/JCO.1997.15.6.2296.
Zotero 插件